SCHEMBL5465784

SCHEMBL5465784

O=Cc1cc(Cl)ccc1OCc1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.52
CCR5 P51681 2/20 0.52
SLC6A2 P23975 1/20 0.51
SLC6A3 Q01959 1/20 0.51
PTGER1 P34995 3/20 0.51
TACR2 P21452 1/20 0.49
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 3/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MRGPRX4 Q96LA9 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5631333 0.88 MAOA (0.51) CCR5ALDH1A1MAPTMAOAMAOB
SCHEMBL29227218 0.85 CCR5 (0.56) SLC6A4CCR5TACR2MAPTMAOA
SCHEMBL1119150 0.85 JAK2 (0.57) SLC6A4CCR5PTGER1TACR2SMN1; SMN2
SCHEMBL5631282 0.83 TUBB1 (0.51) CCR5TACR2ALDH1A1LMNASMN1; SMN2
SCHEMBL17294040 0.82 SLC6A4 (0.57) SLC6A4CCR5TACR2MAPTKMT2A
SCHEMBL9947475 0.82 ALDH1A1 (0.47) CCR5ALDH1A1SMN1; SMN2MAPTMAOA
SCHEMBL12437548 0.82 MAOA (0.47) SLC6A4CCR5SLC6A2SLC6A3ALDH1A1
SCHEMBL275887 0.82 CCR5 (0.62) CCR5ALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL30866193 0.82 CCR5 (0.62) CCR5ALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL5628019 0.82 MAPT (0.51) CCR5PTGER1ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946031-A Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors 北京大学 2024-04-30 CN disclosed
EP-2766344-B1 EP1 RECEPTOR LIGANDS ESTEVE LABOR DR (ES) 2017-05-03 EP disclosed
US-20070082912-A1 Pyrrole compounds for the treatment of prostaglandine mediated diseases GLAXO GROUP LIMITED (GB) 2007-04-12 US disclosed
US-20070072906-A1 Pyrrole compounds GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070072906-A1 Pyrrole compounds GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed
US-20070072906-A1 Pyrrole compounds GLAXO GROUP LIMITED (GB) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072906-A1 Pyrrole compounds PRMT9, EPOR, ADCYAP1R1 SLC6A4 4601/4885CCR5 1513/4885SLC6A2 4727/4885
US-20070082912-A1 Pyrrole compounds for the treatment of prostaglandine mediated diseases PTGER1, PTGDR, PTGIR SLC6A4 4389/4885CCR5 1258/4885SLC6A2 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.